{"name":"Sutro Biopharma, Inc.","slug":"sutro-biopharma","ticker":"STRO","exchange":"NASDAQ","domain":"sutrobio.com","description":"Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung","hq":"South San Francisco, CA","founded":0,"employees":"137","ceo":"","sector":"Biotech — Oncology / ADC","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":39.78,"stockChange":0.18,"stockChangePercent":0.45,"marketCap":"$659M","metrics":{"revenue":102484000,"revenueGrowth":-21.4,"grossMargin":-62.4,"rdSpend":0,"netIncome":-191086000,"cash":141428000,"dividendYield":0,"peRatio":-7.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"STRO-001","genericName":"STRO-001","slug":"stro-001","indication":"Other","status":"phase_1"},{"name":"STRO-004","genericName":"STRO-004","slug":"stro-004","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"STRO-001","genericName":"STRO-001","slug":"stro-001","phase":"phase_1","mechanism":"STRO-001 is an antibody-drug conjugate that binds to CD74, delivering a cytotoxic payload directly to cancer cells expressing this target.","indications":[],"catalyst":""},{"name":"STRO-004","genericName":"STRO-004","slug":"stro-004","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":102484000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":102484000},{"period":"2024-12-31","value":62043000},{"period":"2023-12-31","value":153731000},{"period":"2022-12-31","value":67772000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":166417000,"rdSpendHistory":[{"period":"2025-12-31","value":166417000},{"period":"2024-12-31","value":252043000},{"period":"2023-12-31","value":180425000},{"period":"2022-12-31","value":137171000}],"sgaSpend":41019000,"operatingIncome":-104952000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-104952000},{"period":"2024-12-31","value":-238453000},{"period":"2023-12-31","value":-89278000},{"period":"2022-12-31","value":-128943000}],"netIncome":-191086000,"netIncomeHistory":[{"period":"2025-12-31","value":-191086000},{"period":"2024-12-31","value":-227461000},{"period":"2023-12-31","value":-106793000},{"period":"2022-12-31","value":-119204000}],"eps":-22.49,"epsHistory":[{"period":"2025-12-31","value":-22.49},{"period":"2024-12-31","value":-29.4},{"period":"2023-12-31","value":-17.8},{"period":"2022-12-31","value":-23.5}],"cash":58130000,"cashHistory":[{"period":"2025-12-31","value":58130000},{"period":"2024-12-31","value":190304000},{"period":"2023-12-31","value":69268000},{"period":"2022-12-31","value":47254000}],"totalAssets":173830000,"totalLiabilities":306282000,"totalDebt":15674000,"equity":-132452000,"operatingCashflow":-177231000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-177231000},{"period":"2024-12-31","value":-191540000},{"period":"2023-12-31","value":-111616000},{"period":"2022-12-31","value":3549000}],"capex":-1695000,"capexHistory":[{"period":"2025-12-31","value":-1695000},{"period":"2024-12-31","value":-3098000},{"period":"2023-12-31","value":-4315000},{"period":"2022-12-31","value":-7858000}],"freeCashflow":-178926000,"dividendsPaid":null,"buybacks":0,"employees":137,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8662000,"ebit":-36515000,"ebitda":-34891000,"period":"2025-12-31","revenue":11647000,"epsBasic":null,"netIncome":-46762000,"rdExpense":36642000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-33657000},{"sga":8741000,"ebit":-46450000,"ebitda":-44550000,"period":"2025-09-30","revenue":9693000,"epsBasic":-6.7,"netIncome":-56857000,"rdExpense":39853000,"epsDiluted":-6.7,"grossProfit":null,"operatingIncome":-38901000},{"sga":10343000,"ebit":-826000,"ebitda":1074000,"period":"2025-06-30","revenue":63745000,"epsBasic":-1.4,"netIncome":-11499000,"rdExpense":38325000,"epsDiluted":-1.4,"grossProfit":null,"operatingIncome":15077000},{"sga":13273000,"ebit":-65325000,"ebitda":-63425000,"period":"2025-03-31","revenue":17399000,"epsBasic":-9.1,"netIncome":-75968000,"rdExpense":51597000,"epsDiluted":-9.1,"grossProfit":null,"operatingIncome":-47471000},{"sga":9030000,"ebit":-61398000,"ebitda":-59530000,"period":"2024-12-31","revenue":14809000,"epsBasic":null,"netIncome":-72443000,"rdExpense":71037000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-65258000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-5.9,"netIncome":null,"rdExpense":null,"epsDiluted":-5.9,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":39.78,"previousClose":39.6,"fiftyTwoWeekHigh":41.88,"fiftyTwoWeekLow":6.7,"fiftyTwoWeekRange":"6.7 - 41.88","fiftyDayAverage":29.08,"twoHundredDayAverage":15.45,"beta":1.64,"enterpriseValue":530308640,"forwardPE":-7.9,"priceToBook":-2.58,"priceToSales":6.43,"enterpriseToRevenue":5.17,"enterpriseToEbitda":-5.43,"pegRatio":0,"ebitda":-97628000,"ebitdaMargin":-95.3,"freeCashflow":-112393376,"operatingCashflow":-177231008,"totalDebt":15674000,"debtToEquity":0,"currentRatio":2.01,"returnOnAssets":-23.4,"returnOnEquity":0,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":35.73,"targetHighPrice":55,"targetLowPrice":9,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.3,"institutionHeldPercent":51.2,"sharesOutstanding":16567887,"floatShares":13306806,"sharesShort":977108,"shortRatio":4,"shortPercentOfFloat":5.9,"epsTrailing":-22.49,"epsForward":-5.04,"revenuePerShare":12.06,"bookValue":-15.43,"officers":[{"age":54,"name":"Ms. Jane  Chung R.Ph.","title":"CEO & Director"},{"age":52,"name":"Mr. Gregory K. Chow BA, CPA, MBA","title":"Chief Financial Officer"},{"age":61,"name":"Dr. Hans-Peter  Gerber Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Dr. James R. Swartz DSc, Ph.D., Sc.D.","title":"Founder"},{"age":null,"name":"Mr. Devendra  Luhar","title":"Senior Vice President of Technical Operations"},{"age":51,"name":"Mr. David  Pauling J.D., M.A.","title":"Chief Administrative Officer & General Counsel"},{"age":null,"name":"Ms. Kari E. Leetch","title":"Senior VP and Head of People & Culture"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.sutrobio.com","phone":"650 881 6500"}}